Derwood, MD, United States of America

Paul David Robbins


 

Average Co-Inventor Count = 12.0

ph-index = 3

Forward Citations = 97(Granted Patents)


Location History:

  • Upper Nyack, NY (US) (2012 - 2014)
  • Derwood, MD (US) (2014 - 2016)

Company Filing History:


Years Active: 2012-2016

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovations of Paul David Robbins

Introduction

Paul David Robbins is a notable inventor based in Derwood, MD (US). He has made significant contributions to the field of cytotoxic drug development, holding a total of 4 patents. His work focuses on improving drug delivery systems, particularly through innovative conjugate methods.

Latest Patents

Robbins' latest patents include advancements in calicheamicin derivative-carrier conjugates. These patents describe methods for preparing monomeric cytotoxic drug/carrier conjugates with a drug loading significantly higher than previously reported procedures. Additionally, his work emphasizes decreased aggregation and low conjugate fraction (LCF). The patents also cover cytotoxic drug derivative/antibody conjugates, compositions comprising these conjugates, and their various uses. Notably, Robbins has developed monomeric calicheamicin derivative/anti-CD22 antibody conjugates, further enhancing the therapeutic potential of these compounds.

Career Highlights

Robbins is currently associated with Wyeth Holdings Corporation, where he continues to innovate in the pharmaceutical sector. His expertise in drug conjugation techniques has positioned him as a key player in the development of targeted therapies.

Collaborations

Throughout his career, Robbins has collaborated with talented individuals such as Arthur Kunz and Justin Keith Moran. These partnerships have fostered a collaborative environment that enhances the research and development of new therapeutic solutions.

Conclusion

Paul David Robbins exemplifies the spirit of innovation in the pharmaceutical industry. His contributions through patents and collaborations have the potential to significantly impact drug delivery systems and cancer treatment methodologies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…